"The FDA's IND approval for CMND-100 marks a significant step forward in addressing the critical unmet medical needs in AUD, a disease currently lacking effective treatments. Excessive alcohol use is a leading preventable cause of death in the United States, affecting millions of patients and their families. We believe in the potential of our treatment to improve millions of lives in a safe, easy, and efficient way," said Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine. "Approval to start our first-in-human ...

Core Viewpoint - Clearmind Medicine Inc. has submitted an additional patent application to the USPTO as part of its collaboration with SciSparc Ltd. to develop novel psychedelic-derived therapeutics aimed at addressing under-treated health issues, including obesity and addiction [1][3][4]. Company Overview - Clearmind is a clinical-stage biotech company focused on discovering and developing psychedelic-derived therapeutics to tackle significant health problems, particularly alcohol use disorder [4]. - The company currently holds an intellectual property portfolio consisting of eighteen patent families, including 28 granted patents, and aims to expand its patent holdings opportunistically [10]. Collaboration and Patent Applications - In collaboration with SciSparc, Clearmind has filed a total of twelve patent applications with the USPTO for various proprietary compositions, including the combination of SciSparc's PEA and Clearmind's MEAI compound for treating alcohol use disorder, cocaine addiction, and obesity [3][8]. - The latest patent application specifically refers to the proprietary composition of Clearmind's MEAI compound with Palmitoylethanolamide (PEA) for addressing metabolic syndrome and obesity [8]. Market Context - The global obesity treatment market was valued at $15 billion in 2022 and is projected to grow at a rapid revenue CAGR of 10.0% from 2023 to 2032, driven by the rising prevalence of obesity and advancements in weight loss technologies [9].

TEL AVIV, Israel, July 16, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced that an additional patent application with the United States Patent and Trademark Office ("USPTO") was submitted as part of its ongoing collaboration with Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) ("Clearmind"), a clinical-st ...

Company Overview - Clearmind Medicine Inc. is a clinical-stage psychedelic pharmaceutical biotech company focused on developing novel psychedelic-derived therapeutics to address significant health issues, including alcohol use disorder [4][5] - The company has filed multiple patent applications in collaboration with SciSparc Ltd. for various proprietary compositions aimed at treating alcohol use disorder, cocaine addiction, obesity, and related metabolic disorders [3][5] Market Insights - The global obesity treatment market was valued at $15 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 10.0% from 2023 to 2032, driven by the rising prevalence of obesity and advancements in weight loss technologies [2] Intellectual Property - Clearmind's intellectual property portfolio includes eighteen patent families with 28 granted patents, and the company plans to pursue additional patents as opportunities arise [7] - A recent patent application pertains to a novel composition combining Clearmind's MEAI compound with Palmitoylethanolamide (PEA) for treating metabolic syndrome and obesity [6]

Vancouver, Canada, July 12, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announces its participation in the upcoming Psychedelic Medicine – Israel 2024 conference. This event will take place in Tel Aviv, Israel from July 28th to 30th, bringing together leading experts and researchers from ...

Core Insights - Clearmind Medicine Inc. is participating in the Psychedelic Medicine – Israel 2024 conference, which will take place from July 28th to 30th in Tel Aviv, Israel, focusing on psychedelic medicine advancements [1][3] Company Overview - Clearmind is a clinical-stage biotech company dedicated to the discovery and development of novel psychedelic-derived therapeutics aimed at addressing significant under-treated health issues, including alcohol use disorder [9] - The company currently holds an intellectual property portfolio consisting of eighteen patent families and 28 granted patents, with plans to seek additional patents and acquire more intellectual property as opportunities arise [4] Research Presentations - Notable presentations at the conference include research on 5-methoxy-2-aminoindane (MEAI), a mild psychedelic agent, which has shown potential in reducing diet-induced obesity and regulating binge behaviors [6][11] - Dr. Zullof-Shani, CEO of Clearmind, will present on MEAI's potential as a binge behavior regulator, highlighting its innovative application in addiction treatment [8][11] - Research findings indicate that MEAI significantly reduces fat mass, preserves lean mass, improves glucose metabolism, reduces hepatic steatosis, and increases energy expenditure in a diet-induced obesity mouse model [13]

Core Insights - Clearmind Medicine Inc. has received patent approval in Hong Kong for its MEAI-based binge behavior regulator program, enhancing its intellectual property portfolio in the psychedelic space [1] - The company now holds 28 granted patents across 18 patent families, with protections in major jurisdictions including the US, Europe, China, India, and Hong Kong [1][2] - MEAI is a novel psychoactive molecule aimed at reducing alcohol consumption and addressing Alcohol Use Disorder, which affects a significant number of individuals [5][6] Company Overview - Clearmind is a clinical-stage biotech company focused on developing psychedelic-derived therapeutics to address under-treated health issues, particularly alcohol use disorder [6] - The company plans to continue seeking additional patents and expanding its intellectual property portfolio opportunistically [2] Product Focus - The MEAI compound is designed to regulate binge behavior and may also be effective in treating binge drinking, a serious addiction [4][5] - The flagship treatment targets Alcohol Use Disorder and weight loss, which are prevalent health concerns [5]

Vancouver, Canada, June 28, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announces advancement in its proprietary MEAI- based binge behavior regulator program through the granting of patent approval in Hong Kong by the Hong Kong Patent Office This latest patent builds upon Clearmind's broa ...

About Yissum Under the terms of the agreement, Clearmind receives exclusive rights to develop, manufacture, and commercialize novel compounds for treating PTSD and other mental health disorders. Clearmind is responsible for the ongoing development and potential commercialization in line with regulatory guidelines.The agreement includes future milestone payments, royalties on future sales, and commitments to safeguard intellectual property rights. Clearmind is a clinical-stage psychedelic pharmaceutical biot ...

[Condensed Interim Consolidated Financial Statements](index=1&type=section&id=Condensed%20Interim%20Consolidated%20Financial%20Statements) The Company's financial position improved significantly by April 30, 2024, with increased assets and equity, while net loss decreased for the six months ended April 30, 2024, driven by financing activities and fair value adjustments [Condensed Interim Consolidated Statements of Financial Position](index=2&type=section&id=Condensed%20Interim%20Consolidated%20Statements%20of%20Financial%20Position) Total assets significantly increased to **$8.85 million** by April 30, 2024, driven by cash, while liabilities decreased and shareholders' equity substantially rose to **$4.65 million** Condensed Interim Consolidated Statements of Financial Position | Metric | April 30, 2024 (USD) | October 31, 2023 (USD) | | :------------------------------------- | :------------------- | :--------------------- | | Cash and cash equivalents | $8,305,927 | $5,427,739 | | Total current assets | $8,691,064 | $5,794,576 | | Total assets | $8,845,718 | $5,953,288 | | Accounts payable and accrued liabilities | $421,156 | $617,004 | | Derivative warrant liabilities | $3,731,799 | $4,310,379 | | Total current liabilities | $4,199,964 | $4,969,816 | | Total liabilities | $4,199,964 | $4,969,816 | | Total shareholders' equity | $4,645,754 | $983,472 | [Condensed Interim Consolidated Statements of Operations and Comprehensive Loss](index=3&type=section&id=Condensed%20Interim%20Consolidated%20Statements%20of%20Operations%20and%20Comprehensive%20Loss) Net loss significantly improved to **$2.28 million** for the six months ended April 30, 2024, driven by fair value gains on derivative warrants and unrealized investment gains Condensed Interim Consolidated Statements of Operations and Comprehensive Loss | Metric | Six months ended April 30, 2024 (USD) | Six months ended April 30, 2023 (USD) | | :------------------------------------------------- | :------------------------------------ | :------------------------------------ | | General and administrative | $2,137,062 | $2,583,873 | | Research and development, net | $550,434 | $905,202 | | Total operating expenses | $2,687,496 | $3,489,075 | | Changes in fair value of derivative warrant liabilities | $560,145 | $(360,557) | | Unrealized gain (loss) on short-term investment | $415,826 | $(58,749) | | Realized loss on short-term investment | $(423,438) | $0 | | Total finance income (expenses) | $649,735 | $(490,681) | | Loss before taxes | $(2,037,761) | $(3,963,201) | | Tax expenses | $(238,256) | $(12,650) | | Net Loss and Comprehensive loss | $(2,276,017) | $(3,975,851) | | Loss per share, basic and diluted | $(0.96) | $(39.62) | [Condensed Interim Statements of Changes in Shareholders' Equity (Deficit)](index=4&type=section&id=Condensed%20Interim%20Statements%20of%20Changes%20in%20Shareholders'%20Equity%20(Deficit)) Shareholders' equity substantially increased to **$4.65 million** by April 30, 2024, primarily due to **$5.6 million** in new capital from share and warrant issuances and exercises Condensed Interim Statements of Changes in Shareholders' Equity (Deficit) | Metric | October 31, 2023 (USD) | April 30, 2024 (USD) | | :------------------------------------------------- | :--------------------- | :------------------- | | Balance, October 31, 2023 | $983,472 | | | Net loss for the period | | $(2,276,017) | | Issuance of common shares, pre-funded warrants and warrants | | $1,459,815 | | Exercise of warrants | | $4,154,389 | | Issuance of common shares upon vesting of restricted stock units | | $11,935 | | Share-based compensation | | $324,095 | | Balance, April 30, 2024 | | $4,645,754 | - On November 28, 2023, the Company effected a **1-for-30** reverse split of its issued and outstanding common shares, retroactively adjusting all share amounts for periods presented[12](index=12&type=chunk)[16](index=16&type=chunk)[43](index=43&type=chunk) [Condensed Interim Consolidated Statements of Cash Flows](index=5&type=section&id=Condensed%20Interim%20Consolidated%20Statements%20of%20Cash%20Flows) Net cash used in operations decreased to **$2.65 million**, while financing activities provided **$5.46 million**, leading to a **$2.88 million** cash increase and **$8.31 million** total cash Condensed Interim Consolidated Statements of Cash Flows | Metric | Six months ended April 30, 2024 (USD) | Six months ended April 30, 2023 (USD) | | :------------------------------------------------- | :------------------------------------ | :------------------------------------ | | Net loss | $(2,276,017) | $(3,975,851) | | Changes in fair value of derivative warrant liability | $(560,145) | $360,557 | | Share-based compensation | $324,095 | $246,446 | | Net cash used in operating activities | $(2,654,773) | $(4,172,649) | | Net cash generated in investing activities | $78,500 | $0 | | Proceeds from issuance of common shares and warrants, net of issuance costs | $1,824,773 | $9,321,796 | | Proceeds received from exercise of warrants | $3,655,950 | $0 | | Net cash provided by financing activities | $5,461,636 | $9,290,812 | | Net increase in cash and cash equivalents | $2,878,188 | $5,116,930 | | Cash and cash equivalents at end of period | $8,305,927 | $5,245,707 | [Notes to the Condensed Interim Consolidated Financial Statements](index=6&type=section&id=Notes%20to%20the%20Condensed%20Interim%20Consolidated%20Financial%20Statements) These notes provide critical details on the Company's operations, accounting policies, financial instruments, and risk management, highlighting its going concern status and capital structure [1. Nature of Operations and Going Concern](index=6&type=section&id=1.%20Nature%20of%20Operations%20and%20Going%20Concern) Clearmind Medicine Inc., a clinical pharmaceutical R&D company, faces going concern risks due to no revenue and negative cash flows, despite management's financing plans - Clearmind Medicine Inc. is a clinical pharmaceutical company engaged in phase I/IIa clinical trials of novel psychedelic medicines, with its R&D arm in Israel[40](index=40&type=chunk) - The Company trades under the symbol 'CMND' on Nasdaq and 'CWY' on the Frankfurt Stock Exchange, having voluntarily delisted from the Canadian Securities Exchange on March 14, 2024[20](index=20&type=chunk) - The Company has not generated any revenues for the six months ended April 30, 2024, and has negative cash flows from operations of **$2,654,773**, with an accumulated deficit of **$21,044,080**. Its continued operations depend on obtaining additional financing, which raises substantial doubt about its ability to continue as a going concern[42](index=42&type=chunk) [a. Company Overview and Listing](index=6&type=section&id=a.%20Company%20Overview%20and%20Listing) [b. Going Concern Assessment](index=6&type=section&id=b.%20Going%20Concern%20Assessment) [c. Reverse Share Split](index=6&type=section&id=c.%20Reverse%20Share%20Split) [2. Material Accounting Policy Information](index=7&type=section&id=2.%20Material%20Accounting%20Policy%20Information) Financial statements adhere to IFRS, using USD as functional currency, with key estimates for warrant liabilities and critical judgments on going concern status - The financial statements are prepared under IFRS on a historical cost basis, with financial assets and liabilities (including derivatives) presented at fair value through profit or loss (FVTPL), and are presented in United States dollars[24](index=24&type=chunk) - The Company adopted amendments to IAS 1, replacing 'significant accounting policies' with 'material accounting policy information', emphasizing disclosure of information that can reasonably influence user decisions[26](index=26&type=chunk)[47](index=47&type=chunk) - Significant estimates include warrant liability valuation using the Black-Scholes option pricing model, which relies on subjective assumptions like expected stock price volatility, expected life of warrants, and probability of future adjustment events[29](index=29&type=chunk)[49](index=49&type=chunk)[50](index=50&type=chunk)[72](index=72&type=chunk) - A critical judgment is the application of the going concern assumption, acknowledging material uncertainties that raise substantial doubt about the Company's ability to continue[30](index=30&type=chunk)[51](index=51&type=chunk) [a. Basis of Presentation](index=7&type=section&id=a.%20Basis%20of%20Presentation) [b. Unaudited Interim Financial Information](index=7&type=section&id=b.%20Unaudited%20Interim%20Financial%20Information) [c. Significant Accounting Estimates and Judgments](index=8&type=section&id=c.%20Significant%20Accounting%20Estimates%20and%20Judgments) [3. Short-term Investment](index=9&type=section&id=3.%20Short-term%20Investment) The Company fully disposed of its XYLO short-term investment for **$78,500**, incurring a net realized loss of **$7,612** during the period - The Company sold all XYLO shares for **$78,500**, recording a net realized loss of **$7,612** during the six months ended April 30, 2024[31](index=31&type=chunk) Short-term Investment | Metric | October 31, 2023 (USD) | Disposals (USD) | Net realized loss (USD) | April 30, 2024 (USD) | | :---------------- | :--------------------- | :-------------- | :---------------------- | :------------------- | | XYLO – Shares | $86,112 | $78,500 | $(7,612) | $0 | [4. Related Party Transactions](index=9&type=section&id=4.%20Related%20Party%20Transactions) Related party transactions include **$501,244** in key management compensation, R&D cooperation with SciSparc, and an early terminated office lease Compensation to Key Management Personnel | Metric | Six months ended April 30, 2024 (USD) | Six months ended April 30, 2023 (USD) | | :-------------------------- | :------------------------------------ | :------------------------------------ | | Officers: Consulting fees | $248,274 | $220,501 | | Officers: Share based compensation | $41,555 | $75,380 | | Directors: Directors' fees | $125,525 | $80,976 | | Directors: Share based compensation | $85,890 | $78,124 | | Total compensation | $501,244 | $454,981 | - The Company has a cooperation agreement with SciSparc Ltd. for a feasibility study using certain molecules, which has resulted in **nine patent applications**. Certain officers and directors of the Company also operate or manage SciSparc[54](index=54&type=chunk)[55](index=55&type=chunk) - For the six months ended April 30, 2024, the Company incurred **$22,808** in R&D expenses under the Cooperation Agreement, and **$105,022** is owed to the Company by SciSparc[77](index=77&type=chunk) - The office lease agreement with SciSparc in Tel Aviv was terminated early on March 31, 2024, resulting in approximately **$15,000** in early termination fees and **$3,600** to a broker, recorded as general and administrative expenses[56](index=56&type=chunk)[78](index=78&type=chunk) [a. Compensation to Key Management Personnel](index=9&type=section&id=a.%20Compensation%20to%20Key%20Management%20Personnel) [b. Cooperation Agreement with SciSparc Ltd](index=10&type=section&id=b.%20Cooperation%20Agreement%20with%20SciSparc%20Ltd) [c. Office Lease Agreement with SciSparc Ltd](index=10&type=section&id=c.%20Office%20Lease%20Agreement%20with%20SciSparc%20Ltd) [5. Derivative Warrant Liabilities](index=11&type=section&id=5.%20Derivative%20Warrant%20Liabilities) Derivative warrant liabilities decreased to **$3.73 million** by April 30, 2024, driven by a **$560,145** revaluation gain and warrant exercises, despite new issuances - The Company recorded a gain on the revaluation of total derivative warrant liabilities of **$560,145** for the six months ended April 30, 2024[85](index=85&type=chunk) Derivative Warrant Liabilities | Metric | Amount (USD) | | :------------------------------------ | :------------- | | Balance as of October 31, 2023 | $4,310,379 | | Issuance of January 2024 Warrants | $480,004 | | Exercise of warrants | $(498,439) | | Changes in fair value of warrants | $(560,145) | | Balance as of April 30, 2024 | $3,731,799 | - Exercise prices for April 2023 and September 2023 Warrants were reduced to **$1.077** following the January 2024 Public Offering, which included common shares at a lower price. This led to increased common shares per warrant[58](index=58&type=chunk)[60](index=60&type=chunk) - During the period, **2,219** April 2023 Warrants were exercised into **20,245** common shares, **16,334** September 2023 Warrants into **81,469** common shares, and **30,200** January 2024 Warrants into **30,200** common shares[59](index=59&type=chunk)[61](index=61&type=chunk)[62](index=62&type=chunk) [6. Share Capital](index=13&type=section&id=6.%20Share%20Capital) Common shares outstanding significantly increased to **3,310,528** after a 1-for-30 consolidation, with **$1.82 million** from offerings and **$3.66 million** from warrant exercises - As of April 30, 2024, the number of common shares issued and outstanding was **3,310,528**, a substantial increase from **607,337** on October 31, 2023[65](index=65&type=chunk) - On November 28, 2023, the Company effected a **1-for-30** share consolidation, retroactively restating all share amounts[107](index=107&type=chunk) - On January 16, 2024, the Company completed a registered direct offering and private placement, issuing **1,468,000** Common Shares, **32,000** pre-funded warrants, and **1,500,000** unregistered common warrants, generating net proceeds of **$1,824,773**[87](index=87&type=chunk) - Between November 29, 2023, and March 2, 2024, various warrants were exercised into a total of **1,194,102** shares, generating gross proceeds of **$3,655,950**[108](index=108&type=chunk)[109](index=109&type=chunk)[19](index=19&type=chunk) [a. Authorized Share Capital](index=13&type=section&id=a.%20Authorized%20Share%20Capital) [b. Share Consolidation](index=13&type=section&id=b.%20Share%20Consolidation) [c. Share Transactions (Six Months Ended April 30, 2024)](index=13&type=section&id=c.%20Share%20Transactions%20(Six%20Months%20Ended%20April%2030%2C%202024)) [d. Share Transactions (Six Months Ended April 30, 2023)](index=14&type=section&id=d.%20Share%20Transactions%20(Six%20Months%20Ended%20April%2030%2C%202023)) [7. Warrants](index=15&type=section&id=7.%20Warrants) Warrants outstanding increased to **1,673,625** by April 30, 2024, with a lower weighted average exercise price of **$1.53**, allowing conversion into **2,925,075** common shares Warrants Outstanding Summary | Metric | October 31, 2023 | April 30, 2024 | | :------------------------------------------------ | :--------------- | :------------- | | Balance, Number of warrants outstanding | 384,369 | 1,673,625 | | Balance, Weighted average exercise price (USD) | $7.90 | $1.53 | | Issuance of January 2024 warrants | | 1,500,000 | | Exercise of warrants | | (202,411) | | Expiration of warrants | | (8,333) | | Number of shares to be issued from exercise of warrants | 826,781 | 2,925,075 | Warrants Outstanding Details | Number of warrants outstanding | Number of shares to be issued from the exercise of warrants | Exercise price (USD) | Expiry date | | :----------------------------- | :-------------------------------------------------------- | :------------------- | :--------------------- | | 1,923 | 1,923 | $243.75 | November 17, 2027 | | 50,299 | 697,520 | $1.077 | April 5, 2028 | | 75 | 75 | $1,309.47 | November 23, 2024 | | 151,528 | 755,757 | $1.077 | September 17, 2028 | | 1,469,800 | 1,469,800 | $1.60 | January 15, 2025 | | **Total: 1,673,625** | **Total: 2,925,075** | | | [8. Stock Options](index=16&type=section&id=8.%20Stock%20Options) The Omnibus Equity Incentive Plan governs **5,521** outstanding stock options with a **$437.73** weighted average exercise price, incurring **$56,870** in expense - The Omnibus Equity Incentive Plan allows for granting options or RSUs up to **20%** of issued and outstanding Common Shares to officers, directors, employees, and consultants[116](index=116&type=chunk) Stock Options Summary | Metric | October 31, 2023 | April 30, 2024 | | :------------------------------------ | :--------------- | :------------- | | Outstanding, Number of options | 5,588 | 5,521 | | Outstanding, Weighted average exercise price (USD$) | $434.81 | $437.73 | | Expired | | (67) | | Exercisable, Number of options | | 4,803 | | Exercisable, Weighted average exercise price (USD$) | | $439.41 | - The portion of total fair value of stock options expensed for the six months ended April 30, 2024, was **$56,870**, compared to **$121,935** in the prior year[98](index=98&type=chunk) Stock Option Valuation Assumptions | Assumption | Six months ended April 30, 2024 | Six months ended April 30, 2023 | | :-------------------------- | :------------------------------ | :------------------------------ | | Risk-free interest rate | 3.89% | 3.89% | | Expected life (in years) | 5.11 | 5.13 | | Expected volatility | 150.79%-161.87% | 113%-118% | [9. Restricted Share Units](index=18&type=section&id=9.%20Restricted%20Share%20Units) **236,981** RSUs were outstanding by April 30, 2024, with **437,765** granted and **200,784** vested, totaling **$267,346** in fair value Restricted Share Units Summary | Metric | October 31, 2023 | April 30, 2024 | | :------------------------------------ | :--------------- | :------------- | | Balance, Number of RSUs | 0 | 236,981 | | Balance, Weighted average issue price (USD$) | $0 | $1.28 | | Granted | | 437,765 | | Vested | | (200,784) | - During the six months ended April 30, 2024, **437,765** RSUs were issued to consultants, directors, and officers, and **200,784** RSUs vested with a fair value of **$267,346**[120](index=120&type=chunk) [10. Financial Instruments and Risk Management](index=19&type=section&id=10.%20Financial%20Instruments%20and%20Risk%20Management) Financial instruments include Level 3 derivative warrant liabilities, with credit, foreign currency, and liquidity risks managed through various strategies Fair Value Measurements | Financial Instrument | April 30, 2024 (Level 3) | | :--------------------------- | :----------------------- | | Derivative warrants liability | $3,731,799 | - The Company's exposure to credit risk is primarily from cash, which is mitigated by placing it with high credit quality financial institutions[129](index=129&type=chunk) - The Company is exposed to foreign currency risk from monetary assets and liabilities denominated in New Israeli Shekel and CAD. A **10%** strengthening or weakening of foreign currency against functional currencies would impact net loss by **$12,086**[3](index=3&type=chunk)[103](index=103&type=chunk)[131](index=131&type=chunk) - The Company is not exposed to significant interest rate risk as it does not have any liabilities with variable rates[4](index=4&type=chunk) - Liquidity risk is managed by ensuring sufficient liquidity to meet financial obligations, relying on timely debt or equity financing[132](index=132&type=chunk) Current Liabilities | Liability Type | April 30, 2024 (Within 1 year) | October 31, 2023 (Within 1 year) | | :--------------------------------- | :----------------------------- | :------------------------------- | | Accounts payable and accrued liabilities | $421,156 | $617,004 | | Due to related parties | $47,009 | $42,433 | | Total | $468,165 | $659,437 | [a. Fair Value Measurements](index=19&type=section&id=a.%20Fair%20Value%20Measurements) [b. Credit Risk](index=19&type=section&id=b.%20Credit%20Risk) [c. Foreign Exchange Rate Risk](index=19&type=section&id=c.%20Foreign%20Exchange%20Rate%20Risk) [d. Interest Rate Risk](index=20&type=section&id=d.%20Interest%20Rate%20Risk) [e. Liquidity Risk](index=20&type=section&id=e.%20Liquidity%20Risk) [11. Capital Management](index=21&type=section&id=11.%20Capital%20Management) Capital management focuses on maintaining going concern status and shareholder returns, with a consistent strategy and no externally imposed capital requirements - The Company manages its capital to maintain its ability to continue as a going concern and to provide returns to shareholders and benefits to other stakeholders[6](index=6&type=chunk) - The capital structure consists of cash and equity, including issued share capital, RSU reserve, warrants reserve, and options reserve[6](index=6&type=chunk) - The Company is not subject to externally imposed capital requirements, and its capital risk management strategy remains unchanged[133](index=133&type=chunk) [12. Segmented Information](index=21&type=section&id=12.%20Segmented%20Information) The Company operates as a single R&D segment in Israel, securing exclusive licensing agreements for psychedelic compounds in addiction and mental health - As of April 30, 2024, the Company has one operating segment: the research and development of novel psychedelic medicine, primarily in Israel[7](index=7&type=chunk) - On January 15, 2024, the Company signed an exclusive long-term licensing agreement with BIRAD for a dedicated cocaine addiction treatment, involving milestone payments and **2.5%** royalties for **15 years** post-commercial sale[127](index=127&type=chunk) - On March 19, 2024, the Company signed an exclusive global patent licensing agreement with Yissum for psychedelic compounds, involving **3%** royalties on sales, annual license fees starting at **$25,000**, and milestone payments of **$400,000** upon Phase III clinical trial enrollment and **$600,000** upon first commercial sale[8](index=8&type=chunk)[138](index=138&type=chunk) [13. Commitments](index=21&type=section&id=13.%20Commitments) Commitments primarily involve lease obligations, specifically the early termination of an office lease agreement with SciSparc Ltd - The Company's lease commitment is detailed in Note 4c, which describes the early termination of an office lease agreement with SciSparc Ltd[135](index=135&type=chunk)